UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy

Aug.11.2022
UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy
The Welsh Tobacco Control Strategy lacks support for e-cigarettes and misses a significant opportunity for smoking cessation, says UKVIA.

The newly released Tobacco Control Strategy (TCS) in Wales has stated that it has not yet developed a position on e-cigarettes. The UKVIA has stated that, given the support of e-cigarettes in other parts of the UK, it will continue to engage with Welsh policymakers.


A plan to reduce smoking rates in Wales and achieve a "smoke-free" status by 2030 has been recently released. However, the plan has been criticized by the UK Vaping Industry Association (UKVIA) for lacking support for electronic cigarettes, which they describe as a missed opportunity. The UKVIA is the largest industry association representing the e-cigarette industry in the United Kingdom.


John Dunne, CEO of UKVIA stated, "While there are many commendable aspects to the strategy for reducing smoking rates in Wales, it is disappointing that the Welsh government hasn't gone further to seize this golden opportunity to embrace and advocate for e-cigarettes as the best and most effective way to help people quit smoking for good.


Although the Welsh TCS did mention e-cigarettes, it was only briefly noted that the Welsh government needs to develop its stance on e-cigarettes.


Dunne went on to say, "For this reason, we will continue to collaborate with the Welsh government, as in the recent example of the Khan review on smoking, which concluded that promoting e-cigarettes is absolutely crucial for achieving a smoke-free UK by 2030.


Welsh TCS has brought up the issue of preventing children and young people from smoking and using e-cigarettes - a topic that UKVIA has strongly advocated for. Dunne stated: "We welcome the Welsh government's plan to prevent young people from accessing e-cigarettes.


As an association, we have called on the UK government to impose stricter regulations on e-cigarette retailers who sell to young people. We recommend a fine of £10,000 for those caught in violation.


Returning to Wales, TCS lacks support for e-cigarettes as a tool to quit smoking. Dunne added, "There is indisputable evidence that e-cigarettes are effective in helping adults quit smoking. Support is growing among the scientific, academic, healthcare, and political communities, all of which now recognize e-cigarettes as an important component in helping smokers quit.


While it is disappointing to see that the Welsh government has not taken a more proactive stance on e-cigarettes, it is important to engage with politicians and decision-makers in the region to showcase the value of these devices and help the country achieve its smoke-free goals. Failing to do so could have serious consequences for Wales' ability to reduce smoking rates and minimize harm.


Meanwhile, in Scotland, a survey of 2,170 individuals found that 41% of respondents reported that e-cigarettes helped them quit smoking. The survey also found that only one-sixth of respondents wished for stricter regulations on e-cigarettes, while half hoped for more relaxed regulations. Scotland's government is currently considering whether to ban in-store promotions of e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals for educational and informational purposes only.


This article does not necessarily represent the views of 2FIRSTS, and 2FIRSTS cannot verify the truth or accuracy of the article's content. The translation of this article is intended only for internal industry discussion and research purposes.


Due to limitations in translation skills, the translated article may not accurately convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regard to any domestic, Hong Kong, Macao, Taiwan, or foreign statements and positions.


All compiled information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives